Tecentriq Approval History
FDA Approved: Yes (First approved May 18, 2016)
Brand name: Tecentriq
Generic name: atezolizumab
Dosage form: Injection
Company: Genentech, Inc.
Treatment for: Bladder Cancer, Non-Small Cell Lung Cancer
Tecentriq (atezolizumab) is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for the treatment of patients with advanced urothelial carcinoma and patients with metastatic non-small cell lung cancer (NSCLC).
Tecentriq is administered via intravenous infusion over 60 minutes every 3 weeks. Patients should be aware that Tecentriq has the potential to cause infection and severe immune-mediated side effects that involve healthy organs. In some cases, treatment may need to be interrupted or discontinued, and corticosteroid treatment may be required.
The most common side effects reported in patients with advanced urothelial carcinoma were fatigue, decreased appetite, nausea, urinary tract infection, fever, and constipation. The most common side effects reported in patients with metastatic non-small cell lung cancer were fatigue, decreased appetite, dyspnea, cough, nausea, musculoskeletal pain, and constipation.
Development History and FDA Approval Process for Tecentriq
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.